Loading...
Thumbnail Image
Publication

Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes

Rabin, Alexandra
Bello, Elisa
Kumar, Saurabh
Zeki, Dalia Abou
Afshari, Khashayar
Deshpande, Mugdha
Francis, Nimmy
Khalighinejad, Farnaz
Umeton, Raffaella
Radu, Irina
... show 6 more
Embargo Expiration Date
Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease with heterogeneous clinical presentations and variable long-term disability accumulation. There are currently no standard criteria to accurately predict disease outcomes. In this study we investigated the cross-sectional relationship between disease phenotype and immune-modulating cytokines and chemokines in cerebrospinal fluid (CSF). We analyzed CSF from 20 DMT-naïve MS patients using Olink Proteomics' Target 96 Inflammation panel and correlated the resulting analytes with respect to (1) disease subtype, (2) patient age and sex, (3) extent of clinical disability, and (4) MRI segmental brain volumes. We found that intrathecal IL-4 correlated with higher Expanded Disability Status Scale (EDSS) scores and longer 25-foot walk times, and CD8A correlated with decreased thalamic volumes and longer 9-hole peg test times. Male sex was associated with higher FGF-19 expression, and Tumefactive MS with elevated CCL4. Several inflammatory markers were correlated with older age at the time of LP. Finally, higher intrathecal IL-33 correlated with increased MS lesion burden and multi-compartment brain atrophy. This study confirms immune heterogeneity underlying CSF profiles in MS, but also identifies several inflammatory protein biomarkers that may be of use for predicting clinical outcomes in future algorithms.

Source

Rabin A, Bello E, Kumar S, Zeki DA, Afshari K, Deshpande M, Francis N, Khalighinejad F, Umeton R, Radu I, Qutab F, Kwong D, Kurban M, Hemond C, Richmond JM, Ionete C. Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes. Sci Rep. 2024 Sep 18;14(1):21793. doi: 10.1038/s41598-024-67769-1. PMID: 39294186; PMCID: PMC11411093.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1038/s41598-024-67769-1
PubMed ID
39294186
Other Identifiers
Notes
Funding and Acknowledgements
Supported by a SPARK grant from the UMass Center for Clinical and Translational Science, grant # UL1-TR001453 (to KA and JMR) and a grant from the Worcester Foundation for Biomedical Research (to JMR and CI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Open Access: This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/. © The Author(s) 2024Attribution-NonCommercial-NoDerivatives 4.0 International